Skip to main content
Premium Trial:

Request an Annual Quote

Lawsuit against Isis over Kynamro Safety Report Dismissed


A lawsuit filed against Isis Pharmaceuticals for allegedly misleading shareholders over claims made about the company's cholesterol-lowering antisense drug Kynamro, which was the subject of a troubling regulatory review, has been dismissed, Gene Silencing News has learned.

The lawsuit, which was filed on behalf of Isis shareholders, claimed that Isis and its management made “materially false and misleading statements regarding the safety and efficacy of the product, as well as reportedly positive results from Kynamro’s clinical trials” (GSN 1/3/2013).

In October, the US Food and Drug Administration published a clinical briefing document noting the incidence of abnormal growths or neoplasms in some patients treated with the drug, which had been submitted as a treatment for homozygous familial hypercholesterolemia. The report also found that three patients treated with Kynamro had died during clinical testing.

On the FDA report, shares of Isis tumbled nearly 22 percent.

Despite the report, the FDA last month approved Kynamro for the treatment of homozygous familial hypercholesterolemia (GSN 1/31/2013). And now, the litigation has been dismissed.

According to a court filing, the plaintiff has voluntarily agreed to drop the suit.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.